CRTC1
CRTC1 (CREB-regulated transcription coactivator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers, Lung cancer, Skin cancer and 5 more.
Overview
Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signalling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.82, animal model 0.26, genetic association 0.26, somatic mutation 0.84). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Adenoid Cystic Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CRTC1 (CREB-regulated transcription coactivator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers, Lung cancer, Skin cancer and 5 more.
- 1 · What it is
CRTC1 (CREB-regulated transcription coactivator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers, Lung cancer, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites.
- 3 · How drugs use it
No product in this corpus aims at CRTC1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:16062 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6UUV9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000105662 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.54, colorectal cancer 0.51, oesophageal cancer 0.51, skin cancer 0.51, lung cancer 0.56, oral cavity cancer 0.56 (GraphQL API, CC0)); IntOGen CRTC1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signalling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates the expression of specific CREB-activated genes such as the steroidogenic gene, StAR. Potent coactivator of PGC1alpha and inducer of mitochondrial biogenesis in muscle cells. In the hippocampus, involved in late-phase long-term potentiation (L-LTP) maintenance at the Schaffer collateral-CA1 synapses. Location: Cytoplasm; Nucleus (UniProt). Locus 19p13.11 (HGNC).
- Salivary gland cancers: IntOGen driver in 1 cohort (ACYC)
- Lung cancer: Open Targets association 0.56 with lung cancer (MONDO_0008903)
- Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575)
- Oesophageal cancer: Open Targets association 0.51 with oesophageal cancer (MONDO_0007576)
- Mucoepidermoid carcinoma: Open Targets association 0.58 with mucoepidermoid carcinoma (MONDO_0003036)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CRTC1" OR ABSTRACT:"CRTC1" OR TITLE:"CREB regulated transcription coactivator 1" OR ABSTRACT:"CREB regulated transcription coactivator 1" OR TITLE:"CREB-regulated transcription coactivator 1" OR ABSTRACT:"CREB-regulated transcription coactivator 1" OR TITLE:"KIAA0616" OR ABSTRACT:"KIAA0616" OR TITLE:"FLJ14027" OR ABSTRACT:"FLJ14027" OR TITLE:"TORC1" OR ABSTRACT:"TORC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRTC1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMAML2
Shares Mucoepidermoid carcinoma, Oral cavity cancer (mouth and tongue), Lung cancer (all types), Skin cancer (all types).
- TargetTRRAP
Shares Salivary gland cancers, Lung cancer (all types), Skin cancer (all types), IntOGen.
- TargetCDX2
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, IntOGen.
- TargetPPP2R1A
Shares Salivary gland cancers, Lung cancer (all types), Skin cancer (all types), IntOGen.
- TargetTENT5C
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Open Targets Platform.
- TargetKAT6A
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, IntOGen.
- TargetESRRA
Shares Adenoid cystic carcinoma, Salivary gland cancers, IntOGen.
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, IntOGen.